Ibogaine Research Database

692 research records indexed from PubMed. Plain-language summaries where available.

Of these, 52 are human clinical studies (trials, observational studies, or case reports), 398 are preclinical (animal or lab) studies, and 112 are reviews or meta-analyses summarizing other researchers’ data. A record appearing here does not by itself mean ibogaine is proven effective for a given condition — see each condition page’s evidence breakdown for what’s actually established.

Compare evidence by condition →

All Studies (692)Depression (56)PTSD (24)Alcohol Addiction (20)Heroin Addiction (16)Opioid Addiction (15)Cocaine Addiction (15)Anxiety (13)Methamphetamine Addiction (12)Traumatic Brain Injury (2)

Studies on Heroin Addiction(12 of 692)

← Back to Heroin Addiction

Ibogaine: Revisiting an Ancient Alkaloid for Modern Opioid Dependence.

Moore, Moore, Alzghari· Substance use & misuse· 2026· PMID: 41404929
Review

Ibogaine is a naturally occurring hallucinogenic alkaloid originally used in ritualistic ceremonies by West Central African tribes for centuries. Ibogaine's rise in popularity in the 1960s was fueled by reports from those with a heroin addiction that claimed ibogaine stemmed thei...

The effect of craving on retention and treatment switching under buprenorphine-naloxone and methadone models of care for non-heroin opioid use disorder: Exploratory analyses from a pragmatic,

McAnulty, Bastien, Abboud· Journal of substance use and addiction treatment· 2025· PMID: 40571059
Randomized Controlled Trial

Though opioid agonist therapies are the mainstay of treatment for opioid use disorder, treatment retention remains suboptimal. Improved prediction of who will remain in treatment could lead to improved treatment outcomes. Whether craving predicts reduced retention in treatment re...

Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models.

Havel, Kruegel, Bechand· Nature communications· 2024· PMID: 39304653
Preclinical (Animal)

Ibogaine and its main metabolite noribogaine provide important molecular prototypes for markedly different treatment of substance use disorders and co-morbid mental health illnesses. However, these compounds present a cardiac safety risk and a highly complex molecular mechanism. ...

Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review.

Bozinoff, Tardelli, Rubin-Kahana· Harm reduction journal· 2022· PMID: 36229831
Systematic Review

Given the ongoing opioid crisis, novel interventions to treat severe opioid use disorder (OUD) are urgently needed. Injectable opioid agonist therapy (iOAT) with diacetylmorphine or hydromorphone is effective for the treatment of severe, treatment-refractory OUD, however barriers...

Death due to consumption of ibogaine: case report.

Aćimović, Atanasijević, Denić· Forensic science, medicine, and pathology· 2021· PMID: 33433774
Case Report

Ibogaine is a psychotropic indole alkaloid extracted from the roots of the Tabernanthe iboga shrub from the Apocynaceae family. Depending on the taken dose, it can lead to stimulant effects, euphoria, visual and auditory hallucinations, along with auditory, olfactory, and gustato...

Ibogaine Consumption With Seizure-Like Episodes, QTc-Prolongation, and Captured Cardiac Dysrhythmias.

Grogan, Gerona, Snow· The Journal of emergency medicine· 2019· PMID: 31630892
Case Report

Ibogaine is a psychoactive indole alkaloid that has been investigated for use as a treatment for opioid addiction. While not commercially available in the United States, it is available via Internet suppliers. Ibogaine use has been associated with significant cardiac and neurolog...

Get Clean or Die Trying.

Nestor· Scientific American· 2016· PMID: 27918503
Unclassified

A case of death due to ibogaine use for heroin addiction: case report.

Jalal, Daher, Hilu· The American journal on addictions· 2013· PMID: 23617876
Case Report

Complementary medicines in psychiatry: review of effectiveness and safety.

Werneke, Turner, Priebe· The British journal of psychiatry : the journal of mental science· 2006· PMID: 16449696
Review

The use of complementary medicines in those with mental health problems is well documented. However, their effectiveness is often not established and they may be less harmless than commonly assumed. To review the complementary medicines routinely encountered in psychiatric practi...

Ibogaine in the treatment of heroin withdrawal.

Mash, Kovera, Pablo· The Alkaloids. Chemistry and biology· 2001· PMID: 11705106
Review

Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.

Mash, Kovera, Pablo· Annals of the New York Academy of Sciences· 2000· PMID: 11085338
Clinical Trial

Ibogaine is an indole alkaloid found in the roots of Tabernanthe Iboga (Apocynaceae family), a rain forest shrub that is native to western Africa. Ibogaine is used by indigenous peoples in low doses to combat fatigue, hunger and thirst, and in higher doses as a sacrament in relig...

Ibogaine in acute opioid withdrawal. An open label case series.

Alper, Lotsof, Frenken· Annals of the New York Academy of Sciences· 2000· PMID: 10911935
Case Series